McVary Kevin T
Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
J Urol. 2006 Jan;175(1):35-42. doi: 10.1016/S0022-5347(05)00032-7.
Evidence of the long-term efficacy and safety of alfuzosin treatment for LUTS indicative of BPH was examined.
An English literature search of MEDLINE, PubMed and proceedings from scientific meetings from 1974 to 2004 was done. Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular.
Currently alpha(1)-adrenergic receptor blocking agents are first line treatment for BPH. Although all alpha-blocking compounds show similar levels of efficacy for LUTS treatment, newer agents such as alfuzosin tend to demonstrate improved selectivity for the prostate and bladder with few vasodilatory effects and they have tolerability advantages over older alpha-blocking compounds. Immediate, sustained and newer extended release alfuzosin formulations significantly improve LUTS indicative of BPH but extended release alfuzosin may be more convenient to administer and it tends to show better vasodilatory tolerability than the older immediate release formulation.
When used to treat BPH, alfuzosin provides symptom relief, decreased residual post-void urine volume and a decreased risk of acute urinary retention, which are maintained during long-term use. Most vasodilatory side effects occur early in treatment and they become less frequent thereafter. Patient quality of life also improves with maximal improvements observed after 12 months of treatment. Continued study will further clarify the physiological, clinical and personal benefits produced by alfuzosin when used for the management of LUTS indicative of BPH.
研究阿夫唑嗪治疗提示良性前列腺增生的下尿路症状（LUTS）的长期疗效和安全性证据。
对1974年至2004年期间的MEDLINE、PubMed以及科学会议论文集进行英文文献检索。检索词包括良性前列腺增生、阿夫唑嗪、治疗、α（1）-肾上腺素能受体阻滞剂、长期、随访、下尿路症状、并发症或不良事件、性功能、尿潴留和心血管。
目前α（1）-肾上腺素能受体阻滞剂是良性前列腺增生的一线治疗药物。尽管所有α阻滞剂化合物在治疗LUTS方面显示出相似的疗效水平，但阿夫唑嗪等新型药物对前列腺和膀胱的选择性更高，血管舒张作用较少，且与 older alpha-blocking compounds相比具有耐受性优势。速释、缓释和新型缓释阿夫唑嗪制剂均能显著改善提示良性前列腺增生的LUTS，但缓释阿夫唑嗪给药可能更方便，且与旧的速释制剂相比，其血管舒张耐受性往往更好。
用于治疗良性前列腺增生时，阿夫唑嗪可缓解症状，减少排尿后残余尿量，并降低急性尿潴留风险，这些效果在长期使用中得以维持。大多数血管舒张副作用在治疗早期出现，此后频率降低。患者生活质量也有所改善，治疗12个月后观察到最大改善。持续研究将进一步阐明阿夫唑嗪用于管理提示良性前列腺增生的LUTS时产生的生理、临床和个人益处。
